Multimodal management of malignant pleural mesothelioma: Where are we today?

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 754-764

  Van Schil, Paul E ^a   Opitz, Isabelle ^b   Weder, Walter ^b   De Laet, Christophe ^a   Domen, Andreas ^a   Lauwers, Patrick ^a   Hendriks, Jeroen M ^a   Van Meerbeeck, Jan P ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CISPLATIN; GEMCITABINE; PEMETREXED;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG RESECTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL TIME; THORACOSCOPY; TUMOR VOLUME; VIDEO ASSISTED THORACOSCOPIC SURGERY; AGED; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MESOTHELIOMA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURAL NEOPLASMS; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; THORAX SURGERY; TREATMENT OUTCOME;

AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PNEUMONECTOMY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RESEARCH DESIGN; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 84904721860     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00207213     Document Type: Article

References (70)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 11-465.
2. Ambrogi VMT. Clinical and biologic prognostic factors in malignant pleural mesothelioma. Thorac Cancer 2012; 3: 289-302.
3. Riaz SP, Coupland VH, Luchtenborg M, et al. Mesothelioma incidence projections in South East England. Eur Respir J 2012; 40: 965-968.
4. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-1128.
5. Van Schil P. Malignant pleural mesothelioma: staging systems. Lung Cancer 2005; 49: Suppl. 1, S45-S48.
6. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.
7. Labby ZE, Armato SG 3rd, Kindler HL, et al. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 1728-1734.
8. Armato SG 3rd, Labby ZE, Coolen J, et al. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2013; 82: 190-196.
9. Frauenfelder T, Tutic M, Weder W, et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 2011; 38: 162-168.
10. Labby ZE, Nowak AK, Dignam JJ, et al. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol 2013; 24: 999-1005.
11. Shersher DD, Liptay MJ. Multimodality treatment of pleural mesothelioma. Surg Oncol Clin N Am 2013; 22: 345-355.
12. Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 2013; 145: 909-910.
13. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012; 7: 1631-1639.
14. Van Schil PE. Treatment of mesothelioma: still a long way to go! Chin J Cancer Res 2013; 25: 132-133.
15. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145-152.
16. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
17. Francart J, Legrand C, Sylvester R, et al. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma - the EORTC Lung Cancer Group. J Clin Oncol 2006; 24: 3007-3012.
18. Gill RR, Richards WG, Yeap BY, et al. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol 2012; 198: 359-363.
19. Opitz IFM, Stahel RA, Weder W. A clinical-based risk score for decision making for surgery after induction chemotherapy in maignant pleural mesothelioma patients. J Clin Oncol 2013; 31: Suppl., 7587.
20. Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg 2012; 1: 438-448.
21. Kindler HL. Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol 2012; 7: 1623-1624.
22. Meuris K, Hertoghs M, Lauwers P, et al. Subtotal pleurectomy by video-assisted thoracic surgery for metastatic pleuritis. MMCTS 2012; mms008: 10.1093/mmcts/mms008.
23. Halstead JC, Lim E, Venkateswaran RM, et al. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol 2005; 31: 314-320.
24. Rintoul RCRA, Edwards J, Waller DA, et al. MesoVATS: a multi-centre randomised controlled trial of video-assited thoracoscopic pleurectomy versus talc pleurodesis in malignant pleural mesothelioma. J Thorac Oncol 2013; 8: Suppl. 2, S2-S3.
25. Genc O, Petrou M, Ladas G, et al. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000; 18: 143-146.
26. Sioris T, Sihvo E, Salo J, et al. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol 2009; 35: 546-551.
27. Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011; 6: 1304-1312.
28. Singhal S, Kaiser LR. Malignant mesothelioma: options for management. Surg Clin N Am 2002; 82: 797-831.
29. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-244.
30. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.
31. Green J, Dundar Y, Dodd S, et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database Syst Rev 2007; 1: CD005574.
32. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.
33. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620-626.
34. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788-795.
35. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-758.
36. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004; 91: 9-10.
37. Lee C, Bayman N, Swindell R, et al. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer 2009; 66: 150-156.
38. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22.
39. Davies HE, Musk AW, Lee YC. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Curr Op Pulm Med 2008; 14: 326-330.
40. Ung YC, Yu E, Falkson C, et al. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol 2006; 80: 13-18.
41. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202.
42. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-1418.
43. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010; 36: 1362-1369.
44. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-3013.
45. Treasure T, Utley M. Mesothelioma: benefit from surgical resection is questionable. J Thorac Oncol 2007; 2: 885-886.
46. Treasure T, Tan C, Lang-Lazdunski L, et al. The MARS trial: mesothelioma and radical surgery. Interac Cardiovas Thoracic Surg 2006; 5: 58-59.
47. Treasure T, Waller D, Tan C, et al. The Mesothelioma and Radical Surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol 2009; 4: 1254-1258.
48. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12: 763-772.
49. Steele JP. Randomised trial of extended pleurectomy and decortication (EPD) with pemetrexed and platinum chemotherapy versus pemetrexed and platinum alone in patients with malignant pleural mesothelioma ("MARS-2"). Proc IMIG 2012; 2012: P3.22.
50. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011; 12: 1093-1094.
51. Cao CQ, Yan TD, Bannon PG, et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010; 5: 1692-1703.
52. Cao C, Tian D, Manganas C, et al. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg 2012; 1: 428-437.
53. Hiddinga BI, van Meerbeeck JP. Surgery in mesothelioma-where do we go after MARS? J Thorac Oncol 2013; 8: 525-529.
54. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 737-743.
55. Weyant MJ. Is it time to consider pleurectomy and decortication as the only surgical treatment for malignant pleural mesothelioma? J Thorac Oncol 2012; 7: 629-630.
56. Cao C, Tian DH, Pataky KA, et al. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer 2013; 81: 319-327.
57. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495.
58. Asbestos Diseases Research Institute. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. www.adri.org.au/documents/ Guidelines-for-the-diagnosis-and-treatment-of-malignant-pleural-mesothelioma. pdf Date last accessed: 2013. Date last updated: July 2013.
59. Swiss Group for Clinical Cancer Research. Project Group Lung Cancer. http://sakk.ch/en/about-sakk/organization/research-groups/project-group-lung- cancer/ Date last accessed: January 25, 2014. Date last updated: 2014.
60. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84: 1685-1692.
61. Memorial Sloan-Kettering Cancer Center. Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy. www.clinicaltrials.gov/ct2/show/NCT00715611 Date last accessed: January 25, 2014. Date last updated: January 17, 2014.
62. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2012; 83: 1278-1283.
63. De Perrot MMO, Feld R, Leighl N, et al. Five-year experience with accelerated induction hypofractionated hemithoracic intensity modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM). J Thorac Oncol 2013; 8: Suppl. 2, S345-S346.
64. Lang-Lazdunski L, Bille A, Belcher E, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidoneiodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1746-1752.
65. Sugarbaker DJ, Gill RR, Yeap BY, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013; 145: 955-963.
66. Haas AR, Sterman DH. Intracavitary therapeutics for pleural malignancies. Clin Chest Med 2013; 34: 501-513.
67. Opitz ILO, Meerang M, Friess M, et al. Intracavitary cisplatin-fibrin chemotherapy after resection for malignant pleural mesothelioma patients (Influence-meso) - preliminary results. J Thorac Oncol 2013; 8: Suppl. 2, S343.
68. Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10: 266-283.
69. Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012; 1: 472-480.
70. Lang-Lazdunski L, Van Meerbeeck JP, Vermassen F. EORTC randomised phase II study of extended pleurectomy/decortication (e-P/D) preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (MPM). Proc IMIG 2012; 2012: P4.14.